Effects of Paraoxonase 1 Polymorphisms on Risk of Recurrence in Chinese Ischemic Stroke Survivors Receiving Clopidogrel
孙文珊,李军荣,李永坤,张治中,曹立平,白文,陈季南,刘新峰,徐格林
DOI: https://doi.org/10.3760/cma.j.issn.1006-7876.2015.01.004
2015-01-01
Abstract:Objective To investigate the impact of paraoxonase 1 (PON1) Q192R as well as L55M genotypes on the risk of recurrent ischemic events in a cohort of Chinese patients treated with clopidogrel.Methods Consecutive patients with ischemic stroke registered in Nanjing Stroke Registry Program between May 2008 and April 2010 were enrolled in this study.Single-nucleotide polymorphisms genotyped included PON1Q192R,PON1L55M.Genotypes were determined by improved multiple ligase detection reaction.All patients were genotyped and clinical outcomes were determined with three monthly follow-up.The primary endpoint was a composite of vascular death,and nonfatal ischemic stroke and myocardial infarction and secondary endpoint was bleeding events.Cumulative risk of primary endpoint according to genotypes was presented with Kaplan-Meier survival curve.Differences between genotypes in respect to clinical events were assessed by univariate and multivariable Cox proportional-hazards model.Results Of the enrolled 625 patients,during the mean follow-up of (12.7 ± 5.1) months,vascular death was observed in 13 (2.1％),non-fatal ischemic stroke in 65 (10.4％),and non-fatal myocardial infarction in 7 (1.1％) patients.The overall primary endpoint was observed in 85 (13.6％) patients.Bleeding events were found in 13 (1.2％) patients.Frequencies of PON1Q192 and PON155M alleles were 38.1％ (238/ 625) and 2.8％ (17.5/325),respectively.Primary endpoint was observed in 62 (15.7％) of 394 patients with QQ/QR,in 23 (10.0％) of 231 patients with RR during follow-up.PON1Q192 alleles were associated with increased risk of adverse clinical events (HR =1.68,95％ CI 1.04-2.71,P =0.030).Adjusting for age,sex,and major cardiovascular risk factors,PON1Q192 alleles carriage was independently associated with stroke recurrence (HR =2.39,95％ CI 1.33-4.29,P =0.004).No relationship between PON1L55M genetic polymorphisms and clinical outcomes was detected.Conclusions PON1Q192R polymorphisms may be determinants of clinical efficacy of clopidogrel in ischemic stroke patients in China.A worse clinical outcome occurred in patients carrying PON1Q192 who were treated with clopidogrel after ischemic stroke.